Tactile Medical Appoints Eric Pauls as Senior Vice President of Sales
April 20 2021 - 4:05PM
Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:
TCMD), a medical technology company focused on developing medical
devices for the treatment of chronic diseases at home, today
announced the appointment of Eric Pauls to the position of Senior
Vice President of Sales, effective May 1, 2021. Mr. Pauls will
succeed Bryan Rishe, who is retiring in May.
“Eric is a strategic leader with over 20 years of experience in
the healthcare industry and a proven history of building scale and
leading high-performance teams,” said Dan Reuvers, President and
Chief Executive Officer of Tactile Medical. “His career has been
dedicated to establishing treatments as the standard of care in
various chronic diseases, including obstructive sleep apnea and
chronic pulmonary conditions. Moreover, Eric brings a strong
understanding of our business model, having managed the integration
and operations of RespirTech, a Philips acquisition with a wearable
therapy garment that allowed patients to self-administer care at
home. Eric brings the experience to develop and lead a world-class
team focused on the development of lymphedema care and related
chronic conditions.”
Mr. Reuvers continued: “I also want to thank Bryan for his
leadership and dedication, as well as the many contributions that
have shaped Tactile Medical into the successful organization that
it is today. I wish him and his family all the best as he
transitions to retirement.”
“Tactile Medical is a leader in the at-home treatment of chronic
conditions with clinically proven products and a strong track
record of performance,” said Mr. Pauls. “I was drawn to Tactile
Medical because of its unique position in the lymphedema market and
I am excited to lead its continued strategic expansion, working
closely with the rest of the Executive Leadership Team to position
the Company for its next phase of growth.”
Prior to joining Tactile Medical, Mr. Pauls worked for 19 years
in positions of increasing responsibility at Royal Philips (NYSE:
PHG; AEX: PHIA), a leading health technology company. He most
recently held the position of Business Sales Leader for Sleep and
Respiratory Care, North America. In this position, Mr. Pauls was
responsible for a sleep and respiratory business, where he led a
team of 500 sales and support personnel across multiple sales
channels. From 2017 to 2019, he served as Business Segment Leader
for RespirTech, a U.S.-based provider of an in-home wearable
treatment for patients with chronic respiratory conditions, which
was acquired by Philips in 2017.
Mr. Pauls was Vice President of Sales for Key Accounts from 2015
to 2017 and Director of Sales for National Accounts from 2012 to
2014, leading targeted sales teams within Philips’ Sleep and
Respiratory Care business. He held a series of progressively
advancing roles in the 10 years preceding that. Mr. Pauls holds an
M.B.A. from Baker University and a B.S. in Respiratory Care from
the University of Kansas.
About Tactile Medical
Tactile Medical is a leader in developing and marketing at-home
therapy devices that treat chronic swelling conditions such as
lymphedema and chronic venous insufficiency. Tactile Medical’s
Mission is to help people suffering from chronic diseases live
better and care for themselves at home. The Company’s unique
offering includes advanced, clinically proven pneumatic compression
devices, as well as continuity of care services provided by a
national network of product specialists and trainers, reimbursement
experts, patient advocates and clinicians. This combination of
products and services ensures that tens of thousands of patients
annually receive the at-home treatment necessary to better manage
their chronic conditions. Tactile Medical takes pride in the fact
that our solutions help increase clinical efficacy, reduce overall
healthcare costs and improve the quality of life for patients with
chronic conditions.
Legal Notice Regarding Forward-Looking
Statements:
This release contains forward-looking
statements. Forward-looking statements are generally identifiable
by the use of words like “may,” “will,” “should,” “could,”
“expect,” “anticipate,” “estimate,” “believe,” “intend,”
“continue,” “confident,” “outlook,” “guidance,” “project,” “goals,”
“look forward,” “poised,” “designed,” “plan,” “return,” “focused,”
“prospects” or “remain” or the negative of these words or other
variations on these words or comparable terminology. The reader is
cautioned not to put undue reliance on these forward-looking
statements, as these statements are subject to numerous factors and
uncertainties outside of the Company’s control that can make such
statements untrue, including, but not limited to, the impacts of
the COVID-19 pandemic on the Company’s business, financial
condition and results of operations; the course of the COVID-19
pandemic and its impact on general economic, business and market
conditions; the Company’s inability to execute on its plans to
respond to the COVID-19 pandemic; the adequacy of the Company’s
liquidity to pursue its business objectives; the Company’s ability
to obtain reimbursement from third party payers for its products;
loss or retirement of key executives, including prior to
identifying a successor; adverse economic conditions or intense
competition; loss of a key supplier; entry of new competitors and
products; adverse federal, state and local government regulation;
technological obsolescence of the Company’s products; technical
problems with the Company’s research and products; the Company’s
ability to expand its business through strategic acquisitions; the
Company’s ability to integrate acquisitions and related businesses;
price increases for supplies and components; the effects of current
and future U.S. and foreign trade policy and tariff actions; or the
inability to carry out research, development and commercialization
plans. In addition, other factors that could cause actual results
to differ materially are discussed in the Company’s filings with
the SEC. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company undertakes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
Investor Inquiries:
Mike Piccinino, CFA, IRC
Managing Director
Westwicke
investorrelations@tactilemedical.com
Tactile Systems Technology (NASDAQ:TCMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tactile Systems Technology (NASDAQ:TCMD)
Historical Stock Chart
From Apr 2023 to Apr 2024